Rheumatology Advance Access originally published online on August 18, 2006
Rheumatology 2006 45(10):1322; doi:10.1093/rheumatology/kel254
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
OBITUARY |
John H. Glyn
1Princess Margaret Hospital, Windsor, SL4 3SJ and 2St Mary's Hospital, London W2 1NY
| The first 10% of the full text of this article appears below. |
Corticosteroids have been the backbone of treatment of many rheumatological diseases. Most of us recognize the remarkable beneficial effects of steroids, though mindful of the potential longer-term toxicity. In 1949, Philip Hench had demonstrated the miraculous effect of cortisone at the Mayo Clinic, and he invited Will Copeman and Oswald Savage to participate in the first UK studies. The task of personally administering the first injections of